Novel Gene Delivery Development for Spinal Muscular Atrophy

脊髓性肌萎缩症的新型基因传递开发

基本信息

项目摘要

DESCRIPTION (provided by applicant): Spinal muscular atrophy (SMA) is a genetic disorder characterized by the loss of lower motor neurons (LMNs) residing along the entire length of the spinal cord. SMA is caused by a reduction in the expression of the survival motor neuron (SMN) protein. The disease has an incidence of 1 in 6000, and in general, the earlier the symptoms, the shorter lifespan of patients. To date there are no effective therapies, particularly for the most severe forms of this lethal disease. Many lines of evidence support that increased amounts of SMN protein in motor neurons lessen disease severity. To date, therapeutic approaches have mainly focused on evaluating drugs for increasing SMN levels or enhance residual SMN function. Despite years of screening, no drugs have been identified to be fully effective for increasing SMN levels for a restorative therapy. Given the known genetic defect, in which SMN levels are decreased, gene replacement strategies may offer promise for SMA patients. New enhancements in viral vectors are demonstrating significant promise for a number of neurological disorders. This proposal seeks to develop novel gene delivery platforms based on a non-toxic, long-term expressing vector system; adeno-associated virus (AAV). While gene and drug delivery to the spinal cord has remained a challenge, we have recently discovered a unique ability for AAV serotype 9 to be highly efficient at delivering genes to spinal cord motor neurons of new born mice following vascular delivery. Indeed, in some areas of the spinal cord, over 90% of motor neurons were targeted by an AAV9-GFP marker gene, demonstrating the potential for AAV9 to be an effective gene delivery platform for SMA. Furthermore, we have demonstrated preliminary results that AAV9 is efficient at delivering genes to skeletal muscle across the entire body. These results are meaningful given that AAV9 targets both motor neurons and skeletal muscles, which are significantly affected in this disease. Our proposal seeks to further enhance this delivery platform in efforts to develop successful treatment strategies in SMA. This work will provide important information for translating an SMN gene replacement strategy to the clinic for SMA patients and provide needed information in efforts to develop an Investigational New Drug (IND) application. The aims of this proposal are specific goals for this NINDS developmental program to advance promising therapies to the clinic. Aim 1: Optimize vascular injection of AAV9-GFP to neonatal animals for maximal gene delivery to lower motor neurons. Aim 2: Evaluate optimal delivery of AAV9 expressing SMN for neonatal gene replacement in a mouse model of Type 2 SMA for improved function and survival. PUBLIC HEALTH RELEVANCE: Spinal muscular atrophy (SMA) is a genetic disorder characterized by the loss of lower motor neurons (LMNs) residing along the entire length of the spinal cord. To date, therapeutic approaches have mainly focused on evaluating drugs for increasing SMN levels or enhance residual SMN function. Despite years of screening, no drugs have been identified to be fully effective for increasing SMN levels for a restorative therapy. Given the known genetic defect, in which SMN levels are decreased, gene replacement strategies may offer promise for SMA patients. We have discovered a novel delivery platform for highly efficient targeting of motor neurons in neonatal animals. We will develop these findings for the potential to translate into human SMA clinical trials.
描述(由申请人提供):脊髓性肌萎缩症(SMA)是一种遗传性疾病,其特征是位于沿着脊髓全长的下运动神经元(LMN)缺失。SMA是由运动神经元存活(SMN)蛋白表达减少引起的。这种疾病的发病率为1/6000,一般来说,症状越早,患者的寿命越短。到目前为止,还没有有效的治疗方法,特别是对于这种致命疾病的最严重形式。许多证据支持运动神经元中SMN蛋白量的增加可以减轻疾病的严重程度。迄今为止,治疗方法主要集中于评估用于增加SMN水平或增强残余SMN功能的药物。尽管进行了多年的筛选,但尚未确定任何药物可完全有效地提高SMN水平以进行恢复性治疗。鉴于已知的遗传缺陷,其中SMN水平降低,基因替代策略可能为SMA患者提供希望。病毒载体的新增强表现出对许多神经系统疾病的重大承诺。该提案旨在开发基于无毒、长期表达载体系统的新型基因递送平台;腺相关病毒(AAV)。虽然基因和药物递送到脊髓仍然是一个挑战,但我们最近发现了AAV血清型9在血管递送后将基因高效递送到新生小鼠的脊髓运动神经元的独特能力。事实上,在脊髓的某些区域,超过90%的运动神经元被AAV 9-GFP标记基因靶向,这表明AAV 9有可能成为SMA的有效基因递送平台。此外,我们已经证明了AAV 9在将基因递送到整个身体的骨骼肌方面是有效的初步结果。考虑到AAV 9靶向运动神经元和骨骼肌,这些结果是有意义的,运动神经元和骨骼肌在这种疾病中受到显著影响。我们的提案旨在进一步加强这一交付平台,以努力开发成功的SMA治疗策略。这项工作将为SMA患者将SMN基因替代策略转化为临床提供重要信息,并为开发研究性新药(IND)申请提供所需信息。该提案的目的是NINDS发展计划的具体目标,以将有前途的疗法推向临床。目的1:优化AAV 9-GFP对新生动物的血管注射,以最大限度地将基因递送至下运动神经元。目标二:在2型SMA小鼠模型中评估表达SMN的AAV 9用于新生儿基因置换的最佳递送,以改善功能和存活。 公共卫生关系:脊髓性肌萎缩症(SMA)是一种遗传性疾病,其特征是位于沿着整个脊髓长度的下运动神经元(LMN)丢失。迄今为止,治疗方法主要集中于评估用于增加SMN水平或增强残余SMN功能的药物。尽管进行了多年的筛选,但尚未确定任何药物可完全有效地提高SMN水平以进行恢复性治疗。鉴于已知的遗传缺陷,其中SMN水平降低,基因替代策略可能为SMA患者提供希望。我们已经发现了一种新的递送平台,用于高效靶向新生动物的运动神经元。我们将开发这些发现,以便将其转化为人类SMA临床试验。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(2)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Brian K. Kaspar其他文献

914. Recombinant AAV Gene Delivery of Follistatin for Muscle Enhancement in Models of Muscular Dystrophy
  • DOI:
    10.1016/j.ymthe.2006.08.1004
  • 发表时间:
    2006-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    Liza Rizo;Chris Shilling;Amanda Haidet;Priya Umapathi Umapathi;Zarife Sahenk;Jerry R. Mendell;Brian K. Kaspar
  • 通讯作者:
    Brian K. Kaspar
Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager
  • DOI:
    10.1182/blood-2024-198463
  • 发表时间:
    2024-11-05
  • 期刊:
  • 影响因子:
  • 作者:
    Mark A Currier;Allen Reha;Brian Hutzen;Pin-Yi Wang;Chun-yu Chen;Andrea Glaspell;Siddhi Nath Paudel;Akila S Venkataramany;Debashree Das;Danielle Hanlon;Allan A. Kaspar;Samit Varma;Brian K. Kaspar;Jacob G. Scott;Pablo Morales;Peter Ralph;Tonny Johnson;Tania L. Weiss;Timothy P Cripe
  • 通讯作者:
    Timothy P Cripe
245. Delivery of IGF-1 in the Spinal Cord of a Mouse Model of ALS after Intraparenchymal Injection of an Adeno-Associated Vector
  • DOI:
    10.1016/j.ymthe.2006.08.272
  • 发表时间:
    2006-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    Christine Haenggeli;Angelo C. Lepore;Natalie Perez;Brian K. Kaspar;Jeffrey D. Rothstein
  • 通讯作者:
    Jeffrey D. Rothstein
1062. Intracerebellar Injection of AAV-IGF-1 Improves Motor Function and Extends Survival in a Mouse Model of Amyotrophic Lateral Sclerosis
  • DOI:
    10.1016/j.ymthe.2006.08.1160
  • 发表时间:
    2006-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    James C. Dodge;Marco A. Passini;Jennifer Clarke;Liza Grissett;Soo Hyun Kim;Rita Wen;Tatyana V. Taksir;Denise A. Griffiths;Seng H. Cheng;Brian K. Kaspar;Lamya S. Shihabuddin
  • 通讯作者:
    Lamya S. Shihabuddin

Brian K. Kaspar的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Brian K. Kaspar', 18)}}的其他基金

Translating a CSF delivered AAV9-SMN for treatment of Spinal Muscular Atrophy
转化 CSF 递送的 AAV9-SMN 来治疗脊髓性肌萎缩症
  • 批准号:
    8604757
  • 财政年份:
    2013
  • 资助金额:
    $ 15.75万
  • 项目类别:
Translating a CSF delivered AAV9-SMN for treatment of Spinal Muscular Atrophy
转化 CSF 递送的 AAV9-SMN 来治疗脊髓性肌萎缩症
  • 批准号:
    8422417
  • 财政年份:
    2013
  • 资助金额:
    $ 15.75万
  • 项目类别:
Defining a clinically relevant time point for astrocyte targeted therapy in ALS
确定 ALS 星形胶质细胞靶向治疗的临床相关时间点
  • 批准号:
    8392831
  • 财政年份:
    2012
  • 资助金额:
    $ 15.75万
  • 项目类别:
Defining a clinically relevant time point for astrocyte targeted therapy in ALS
确定 ALS 星形胶质细胞靶向治疗的临床相关时间点
  • 批准号:
    8484883
  • 财政年份:
    2012
  • 资助金额:
    $ 15.75万
  • 项目类别:
Role of Potent Trophic Factors on Glia and Motor Neurons in ALS
强效营养因子对 ALS 中神经胶质细胞和运动神经元的作用
  • 批准号:
    8536963
  • 财政年份:
    2009
  • 资助金额:
    $ 15.75万
  • 项目类别:
Role of Potent Trophic Factors on Glia and Motor Neurons in ALS
强效营养因子对 ALS 中神经胶质细胞和运动神经元的作用
  • 批准号:
    8107469
  • 财政年份:
    2009
  • 资助金额:
    $ 15.75万
  • 项目类别:
Role of Potent Trophic Factors on Glia and Motor Neurons in ALS
强效营养因子对 ALS 中神经胶质细胞和运动神经元的作用
  • 批准号:
    8300118
  • 财政年份:
    2009
  • 资助金额:
    $ 15.75万
  • 项目类别:
Role of Potent Trophic Factors on Glia and Motor Neurons in ALS
强效营养因子对 ALS 中神经胶质细胞和运动神经元的作用
  • 批准号:
    7740360
  • 财政年份:
    2009
  • 资助金额:
    $ 15.75万
  • 项目类别:
Gene Delivery to the CNS through the Deep Cerebellar Nucleus
通过小脑深部核将基因传递至中枢神经系统
  • 批准号:
    7496399
  • 财政年份:
    2007
  • 资助金额:
    $ 15.75万
  • 项目类别:
Gene Delivery to the CNS through the Deep Cerebellar Nucleus
通过小脑深部核将基因传递至中枢神经系统
  • 批准号:
    7329784
  • 财政年份:
    2007
  • 资助金额:
    $ 15.75万
  • 项目类别:

相似国自然基金

层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
  • 批准号:
    2021JJ40433
  • 批准年份:
    2021
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
  • 批准号:
    32001603
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目
AREA国际经济模型的移植.改进和应用
  • 批准号:
    18870435
  • 批准年份:
    1988
  • 资助金额:
    2.0 万元
  • 项目类别:
    面上项目

相似海外基金

Task Representations in Ventral Tegmental Area Dopamine Neurons across Shifts in Behavioral Strategy and Reward Expectation
腹侧被盖区多巴胺神经元的任务表征跨越行为策略和奖励期望的转变
  • 批准号:
    10679825
  • 财政年份:
    2023
  • 资助金额:
    $ 15.75万
  • 项目类别:
Peer-Delivered, Behavioral Activation Intervention to Improve Polysubstance Use and Retention in Mobile Telemedicine OUD Treatment in an Underserved, Rural Area
同伴提供的行为激活干预可改善服务不足的农村地区移动远程医疗 OUD 治疗中多物质的使用和保留
  • 批准号:
    10578063
  • 财政年份:
    2022
  • 资助金额:
    $ 15.75万
  • 项目类别:
Neural circuit mechanisms underlying behavioral control through corticostriatal pathways in an area- and input-specific manner
通过皮质纹状体通路以区域和输入特定方式进行行为控制的神经回路机制
  • 批准号:
    18H02545
  • 财政年份:
    2018
  • 资助金额:
    $ 15.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Role of the newly identified area in primate dorsomedial prefrontal conrtex in the integrative regulation of behavioral strategies.
新发现的灵长类动物背内侧前额叶皮质区域在行为策略综合调节中的作用。
  • 批准号:
    22500349
  • 财政年份:
    2010
  • 资助金额:
    $ 15.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Validating Area-Level Behavioral Profiles for Cancer Disparities Research
验证癌症差异研究的区域级行为概况
  • 批准号:
    7455950
  • 财政年份:
    2007
  • 资助金额:
    $ 15.75万
  • 项目类别:
Validating Area-Level Behavioral Profiles for Cancer Disparities Research
验证癌症差异研究的区域级行为概况
  • 批准号:
    7305411
  • 财政年份:
    2007
  • 资助金额:
    $ 15.75万
  • 项目类别:
Doctoral Dissertation Improvement: Behavioral Ecology of Chimpanzees Living in a Dry Area, Ugalla, Tanzania
博士论文改进:生活在坦桑尼亚乌加拉干旱地区的黑猩猩的行为生态学
  • 批准号:
    0128157
  • 财政年份:
    2002
  • 资助金额:
    $ 15.75万
  • 项目类别:
    Standard Grant
Dissertation Research: Quantifying Edge, Behavioral, and Climatic Effects on Survivorship Estimates of an Area-Sensitive Non-Migratory Sparrow
论文研究:量化边缘、行为和气候对区域敏感非迁徙麻雀生存估计的影响
  • 批准号:
    9902226
  • 财政年份:
    1999
  • 资助金额:
    $ 15.75万
  • 项目类别:
    Standard Grant
Dissertation Research: Dynamics in Behavioral Adaptation to a Transportation Innovation: A Case Study of the Bay Area Rapid Transit District (BART)
论文研究:交通创新行为适应动态:湾区捷运区 (BART) 案例研究
  • 批准号:
    9712089
  • 财政年份:
    1997
  • 资助金额:
    $ 15.75万
  • 项目类别:
    Standard Grant
CLINICAL STUDY CONCERNING WITH A ROLE OF THE SUPPLEMENTARY MOTOR AREA AND CINGULATE MOTOR AREA IN HUMAN BEHAVIORAL CONTROL
辅助运动区和扣带运动区在人类行为控制中作用的临床研究
  • 批准号:
    07670727
  • 财政年份:
    1995
  • 资助金额:
    $ 15.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了